Singapore, Jun 11, 2009: SOHM, a generic pharmaceutical manufacturer, received Bureau of Food and Drug Administration (BFAD) registration for generic pharmaceutical sales in the Philippines. The company expects that generic pharmaceutical sales in Philippines will enhance the company's earnings per share in the current quarter.

SOHM has set up many large-scale sales channels to take market share in the $1.8 billion Philippines pharmaceutical market which is growing at over 10 percent annually.

SOHM's headquarter is located in North America with manufacturing sites in India. The company's generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and South East Asia.

Vice President for Corporate Strategy at SOHM, Mr Shailesh Shah, said, “SOHM's strategy is to capture specific areas of the Philippines generic drug market and we have been very successful creating sales channels in this under-served market. The current role of the pharmaceutical industry's sales and marketing workforce will be replaced by a new model over the next ten years as the industry shifts from a mass-market to a target-market approach to increase revenue. In view of enormous growth prospects in the Asian pharmaceutical market we are far ahead of our competition in the development and implementation of our Asian sales strategy.”